Publications by authors named "Jennifer Burkey"

Claim this Profile
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT-787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial.
Thomas Capozza, Jennifer Burkey, Jeroen Van De Wetering, Reinhold Kerb, Jennifer Callahan

Clin Transl Sci· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Utility of Novel Urinary Biomarkers in Mice for Drug Development Studies.
Adeyemi O Adedeji, Yi-Zhong Gu, Tony Pourmohamad, Justin Kanerva, Yafei Chen, Jennifer Burkey

Int J Toxicol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the Value of Urine Volume, Creatinine, and Cystatin C for Urinary Biomarkers Normalization for Drug Development Studies.
Adeyemi O Adedeji, Tony Pourmohamad, Yafei Chen, Jennifer Burkey, Catherine J Betts

Int J Toxicol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Rosie Z Yu, Rudy Gunawan, Noah Post, Thomas Zanardi, Shannon Hall, Jennifer Burkey

Nucleic Acid Ther· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Jennifer Burkey

Mol Ther Nucleic Acids· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of Interactions Between an Antisense Oligonucleotide with 2'-O-(2-Methoxyethyl) Modifications and Major Drug Transporters.
Rosie Z Yu, Mark S Warren, Tanya Watanabe, Brandon Nichols, Mirza Jahic, Jennifer Burkey

Nucleic Acid Ther· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Sotirios Tsimikas, Nicholas J Viney, Steven G Hughes, Walter Singleton, Mark J Graham, Jennifer L Burkey

Lancet· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2'-o-(2-methoxyethyl) modifications.
Rosie Z Yu, John S Grundy, Scott P Henry, Tae-Won Kim, Daniel A Norris, Jennifer Burkey

Mol Ther Nucleic Acids· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Mark J Graham, Richard G Lee, Thomas A Bell, Wuxia Fu, Adam E Mullick, Jennifer Burkey

Circ Res· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous quantification of davalintide, a novel amylin-mimetic peptide, and its active metabolite in beagle and rat plasma by online SPE and LC-MS/MS.
Yan Wang, Ying Qu, Chris L Bellows, John S Ahn, Jennifer L Burkey

Bioanalysis· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, Rebecca A Wright, David O Calligaro

J Pharmacol Exp Ther· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition of [14C]ruboxistaurin in humans.
Jennifer L Burkey, Kristina M Campanale, Robert Barbuch, Douglas O'Bannon, James Rash

Drug Metab Dispos· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo metabolism of [14C]ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy.
Robert J Barbuch, Kristina Campanale, Chad E Hadden, Milton Zmijewski, Ping Yi, Jennifer L Burkey

Drug Metab Dispos· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction.
Kwee Poo Yeo, Stephen L Lowe, Ming Tung Lim, James R Voelker, Jennifer L Burkey

Br J Clin Pharmacol· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis